Logo Logo
Switch Language to German
Kruger, Stephan; Haas, Michael; Burger, Philipp Johannes; Ormanns, Steffen; Modest, Dominik Paul; Westphalen, Christoph Benedikt; Kleespies, Axel; Angele, Martin Kurt; Hartwig, Werner; Bruns, Christiane Josephine; Kirchner, Thomas; Werner, Jens; Heinemann, Volker; Boeck, Stefan (2016): Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. In: Journal of Cancer Research and Clinical Oncology, Vol. 142, No. 12: pp. 2585-2591
Full text not available from 'Open Access LMU'.


Acinar cell carcinoma (ACC) of the pancreas is a very rare cancer, constituting 1 % of all malignant non-endocrine pancreatic tumors. Only very limited data exist to guide treatment in patients with advanced ACC. Between 2000 and 2015, 15 patients with ACC were diagnosed and/or treated at our high-volume comprehensive cancer center. Medical records and correlating serum levels of the potential serum tumor markers CA 19-9, CEA and lipase were analyzed retrospectively. A substantial antitumor activity was observed for treatment regimens containing 5-FU and oxaliplatin with partial responses or prolonged disease stabilizations (> 12 months) observed in 6 out of 7 patients (86 %). Activity was also observed for single-agent 5-FU and its oral prodrugs. Serum lipase levels were elevated in 7 of 12 patients with advanced disease (58 %), whereas CEA and CA 19-9 seemed to be of minor importance for ACC (elevated pre-treatment levels in 4/12 and 3/12 cases, respectively). In selected patients, repeated serum lipase measurements were available and accurately predicted response to chemotherapy and relapse after surgery. 5-FU- and oxaliplatin-containing regimens are active in advanced ACC. Lipase kinetics may be a useful novel tool to monitor the course of disease as well as treatment effects in ACC.